These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 27785010

  • 21. Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis.
    Muro S, Yoshisue H, Kostikas K, Olsson P, Gupta P, Wedzicha JA.
    Respirology; 2020 Apr; 25(4):393-400. PubMed ID: 31339215
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: Pooled analysis of SHINE and ARISE.
    Asai K, Hirata K, Hashimoto S, Fukuchi Y, Kitawaki T, Ikeda K, Fogel R, Banerji D.
    Respir Investig; 2016 Nov; 54(6):428-435. PubMed ID: 27886854
    [Abstract] [Full Text] [Related]

  • 23. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.
    Ulrik CS.
    Int J Chron Obstruct Pulmon Dis; 2014 Nov; 9():331-8. PubMed ID: 24729699
    [Abstract] [Full Text] [Related]

  • 24. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
    Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase AM, Lavecchia C, Pethe A, Shu X, D'Andrea P, IRIDIUM trial investigators.
    Lancet Respir Med; 2020 Oct; 8(10):1000-1012. PubMed ID: 32653074
    [Abstract] [Full Text] [Related]

  • 25. Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study.
    Kim CJ, Yoon HK, Park MJ, Yoo KH, Jung KS, Park JW, Lim SY, Shim JJ, Lee YC, Kim YS, Oh YM, Kim S, Yoo CG.
    Int J Chron Obstruct Pulmon Dis; 2017 Oct; 12():1589-1596. PubMed ID: 28615931
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
    Buhl R, Gessner C, Schuermann W, Foerster K, Sieder C, Hiltl S, Korn S.
    Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679
    [Abstract] [Full Text] [Related]

  • 27. Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING).
    Marin JM, Beeh KM, Clemens A, Castellani W, Schaper L, Saralaya D, Gunstone A, Casamor R, Kostikas K, Aalamian-Mattheis M.
    Int J Chron Obstruct Pulmon Dis; 2016 Apr; 11():1425-34. PubMed ID: 27418815
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [Abstract] [Full Text] [Related]

  • 29. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
    Horita N, Kaneko T.
    Int J Chron Obstruct Pulmon Dis; 2015 Dec; 10():813-22. PubMed ID: 25960646
    [Abstract] [Full Text] [Related]

  • 30. Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study).
    Watz H, Mailänder C, Baier M, Kirsten A.
    BMC Pulm Med; 2016 Jun 14; 16(1):95. PubMed ID: 27301417
    [Abstract] [Full Text] [Related]

  • 31. Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study.
    Salomon J, Stolz D, Domenighetti G, Frey JG, Turk AJ, Azzola A, Sigrist T, Fitting JW, Schmidt U, Geiser T, Wild C, Kostikas K, Clemens A, Brutsche M.
    Respir Res; 2017 Jan 11; 18(1):13. PubMed ID: 28077140
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
    LaForce C, Feldman G, Spangenthal S, Eckert JH, Henley M, Patalano F, D'Andrea P.
    Int J Chron Obstruct Pulmon Dis; 2016 Jan 11; 11():1233-43. PubMed ID: 27354782
    [Abstract] [Full Text] [Related]

  • 33. Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA.
    Singh D, Fabbri LM, Vezzoli S, Petruzzelli S, Papi A.
    Int J Chron Obstruct Pulmon Dis; 2019 Jan 11; 14():531-546. PubMed ID: 30880943
    [Abstract] [Full Text] [Related]

  • 34. Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects
.
    Ren S, Sechaud R, Su Z, Tillmann HC, Hara H, Tan X, Hou J, Woessner R, Zhao R.
    Int J Clin Pharmacol Ther; 2017 Feb 11; 55(2):147-155. PubMed ID: 27841152
    [Abstract] [Full Text] [Related]

  • 35. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
    Prakash A, Babu KS, Morjaria JB.
    Int J Chron Obstruct Pulmon Dis; 2015 Feb 11; 10():111-23. PubMed ID: 25609944
    [Abstract] [Full Text] [Related]

  • 36. Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review.
    Jiang FM, Liang ZA, Zheng QL, Wang RC, Luo J, Li CT.
    Lung; 2013 Apr 11; 191(2):135-46. PubMed ID: 23306410
    [Abstract] [Full Text] [Related]

  • 37. Relieving exertional dyspnea during the 3-min constant speed shuttle test in patients with COPD with indacaterol/glycopyrronium versus tiotropium: the RED trial.
    Beaulieu J, Jensen D, O'Donnell DE, Brouillard C, Tracey L, Vincent S, Nadreau É, Bernard E, Bernard S, Maltais F.
    Ther Adv Respir Dis; 2020 Apr 11; 14():1753466620939507. PubMed ID: 32663102
    [No Abstract] [Full Text] [Related]

  • 38. Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.
    Kalberg C, O'Dell D, Galkin D, Newlands A, Fahy WA.
    Drugs R D; 2016 Jun 11; 16(2):217-27. PubMed ID: 27028749
    [Abstract] [Full Text] [Related]

  • 39. Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.
    Ismaila AS, Huisman EL, Punekar YS, Karabis A.
    Int J Chron Obstruct Pulmon Dis; 2015 Jun 11; 10():2495-517. PubMed ID: 26604738
    [Abstract] [Full Text] [Related]

  • 40. AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD.
    Sethi S, Kerwin E, Watz H, Ferguson GT, Mroz RM, Segarra R, Molins E, Jarreta D, Garcia Gil E.
    Int J Chron Obstruct Pulmon Dis; 2019 Jun 11; 14():667-682. PubMed ID: 30962681
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.